Fitness, Health and Nutrition
November 15, 2026
CATEGORY: HEART & CIRCULATION
The heart attacks never slowed down. In the first full-scale test of a drug built to lower lipoprotein(a), an inherited heart-risk particle, monthly injections of pelacarsen cut blood levels by 78%. Over nearly five years, that made no difference: serious heart events struck 12.3% of people on the drug and 12.1% of people on placebo.1 For a risk factor researchers have wanted to treat for decades, the first real answer is no.
Lipoprotein(a), or Lp(a), is a cholesterol-carrying particle in your blood, and your level of it is set almost entirely by your genes. Diet barely moves it. Exercise doesn’t either. It behaves more like height than weight: fixed early, and stubborn for life. The particle drew attention because people born with high levels have heart attacks more often, and large genetic studies pointed to it as a cause rather than a bystander. Statins don’t lower it. So for the millions of people who’ve been told their Lp(a) is high, the number has been something to know and nothing to treat. Pelacarsen, a lab-made snippet of genetic material that tells the liver to make less of the particle, became the first drug to reach a final-stage trial testing whether lowering that level prevents heart attacks.
The trial, called Lp(a)HORIZON, enrolled 8,350 adults in 42 countries, and its results were published in the New England Journal of Medicine.1 Everyone had survived a heart attack or stroke or had diseased leg arteries, and everyone carried an Lp(a) level of at least 70 mg/dL, far above typical. A computer’s random draw decided who got pelacarsen and who got an identical dummy injection; neither patients nor doctors knew which was which. Both groups stayed on strong standard care, and most took high-intensity statins. For a median of 4.7 years, the trial counted cardiovascular deaths, heart attacks, strokes and urgent artery-opening procedures.
On the blood test, pelacarsen worked almost exactly as designed: Lp(a) fell 78.4% at one year, against 3.2% on placebo. On the outcomes that matter, it did nothing. A major heart event came for 511 of 4,157 people on the drug and 503 of 4,165 on placebo. Deaths from any cause ran 5.7% versus 5.9%. People who started at the very highest levels fared no better, and every planned backup analysis landed the same way.1 The injections also carried costs: flu-like reactions in about a third of users, injection-site reactions in a quarter, 19 confirmed severe allergic reactions against none on placebo, and one user in five quitting over side effects.
Lp(a)HORIZON aimed to validate a long-held expectation established by decades of genetic research: reducing the particle will prevent events. That expectation failed, and the researchers are left explaining a gap. One possibility they raise is timing. Genes keep Lp(a) low for a lifetime; the drug lowered it for five years, late in life, after arteries were already damaged. Another is the strength of modern care, since participants’ LDL cholesterol already sat near 65 mg/dL on treatment. What the result doesn’t say is that Lp(a) was a false alarm. A high reading still marks real inherited risk. And it says nothing yet about drugs that push the particle down even harder, which remain in large trials of their own.1 We’ll learn in a few years whether a deeper cut succeeds where this one didn’t.
For educational purposes only — not medical advice. Consult your clinician before acting on this content.
From Fitness, Health and Nutrition: https://fitnesshealthandnutrition.com/2026/11/15/pelacarsen-lpa-lowering-no-heart-benefit/